1. Introduction {#sec0005}
===============

Currently, an estimated 382 million people live with diabetes mellitus worldwide and a further 316 million have impaired glucose tolerance making them high-risk for the disease. In 2013, diabetes caused 5.1 million deaths and cost USD 548 billion in healthcare spending -- 30 percent of the total healthcare expenditure.[@bib0340] Type 2 diabetes mellitus (T2DM) accounts for 90% of all cases[@bib0345] with its incidence increasing and mirroring the worldwide increase in levels of obesity in adults and children. The causes of this epidemic are a complex interaction between genetic and epigenetic factors and societal influences that determine diet and levels of physical activity. The current strategy used for the treatment of T2DM depends on a dual combination of insulin secretagogue and an insulin sensitizer and despite reasonable glycemic control provided by these drugs initially, over time their efficacy tends to diminish. Moreover, side-effects such as severe hypoglycemia, lactic acidosis, idiosyncratic liver cell injury, digestive discomfort, dizziness, and even death are recognized and can limit their use.[@bib0350], [@bib0355] Furthermore, although there is good evidence of mortality reduction with intensive lipid-control strategies in diabetes,[@bib0360] lipid control remains poor using mainstream lipid-lowering medications.[@bib0365] Together, these factors contribute to the healthcare burden associated with T2DM and make a case for new approaches to manage this complex disease.

The use of plants and recognition of their medicinal functions has been documented for millennia. In fact, the development of metformin, a biguanide, was based on the observation that the hypoglycemic effect of *Galega officinalis* (French lilac) was due to the presence of compounds related to guanidine, including an alkaloid called galegine, that were potent hypoglycemic agents.[@bib0370] Renewed interest in phytotherapy in diabetes is identifying a large number of bioactive plant constituents with wide-ranging effects on animal and human glucose and lipid metabolism[@bib0375] which may hold some promise for new therapies. Specifically, addressing the properties of the plant constituents in the composition SR2004 used in this study, *Morus* (mulberry) leaf extracts have been studied in humans and streptozotocin-induced diabetic rat models[@bib0380], [@bib0385], [@bib0390] showing reversible inhibition of small intestinal brush border α-glucosidase activity by the compound 1-deoxynojirimycin (DNJ) found in high concentrations in the leaves, as well as plant flavonoids and high levels of alkaloidal sugar-mimic glycosidase inhibitors found in the leaf *latex*, which together reduce postprandial hyperglycemia.[@bib0395], [@bib0400], [@bib0405], [@bib0410], [@bib0415] Additionally, leaf extracts have insulin secretagogue activity[@bib0420] and reduce peripheral insulin resistance.[@bib0425] Park et al, using diabetic db/db mice to test the antidiabetic properties of Mulberry leaf water extract, also found increased expressions of liver peroxisome proliferator-activated receptor alpha (PPARα) mRNA in liver and PPARγ in adipose tissue.[@bib0430] PPAR receptors are important nuclear hormone receptors involved in glucose and lipid homeostasis through ligand-activated transcriptional regulation whose effects include enhanced peripheral glucose uptake through increasing glucose transporter-4 (GLUT4) expression and translocation in adipocytes,[@bib0435] as well as decreasing hepatic glucose output.[@bib0440]

*Artemisia* (mugwort, wormwood) is a diverse genus of plants that contains up to 400 species. *In vivo* studies have shown enhanced pancreatic beta cell activity,[@bib0445] hepatic glucose metabolism,[@bib0450] reduced peripheral insulin resistance, and increased skeletal muscle glycogen storage.[@bib0455], [@bib0460] Sun et al, in their study of Artemisia extract in women with gestational diabetes, found increased insulin sensitivity with an increase in circulating levels of the adipocytokine adiponectin.[@bib0465] This hormone, secreted by adipocytes (and upregulated by PPAR activation), has an important role in glucose and lipid storage in skeletal muscle and liver, with levels typically lower in patients with T2DM.[@bib0470] Additionally, an ethanol extract from *Artemisia dracunculus* called Tarralin has been demonstrated in a murine diabetic model to potentiate the effect of incretin (GLP1), a gut hormone secreted in response to a meal.[@bib0475] This hormone also has a variety of effects including glucose-dependent insulin secretion, inhibition of glucagon secretion, and a protective effect on pancreatic β-cells.

*Urtica* (nettle) leaf extracts also show potent PPARα/γ activation[@bib0480] and protective effects on pancreatic beta cells exposed to oxidative stress.[@bib0485], [@bib0490], [@bib0495] Several clinical studies in humans have shown glucose reduction in diabetic patients[@bib0500], [@bib0505], [@bib0510] and protective effects in diabetic nephropathy.[@bib0515]

Studies of *Cinnamomum* (cinnamon) bark in T2DM[@bib0520], [@bib0525], [@bib0530], [@bib0535] that include a recent meta-analysis of 10 randomized controlled trials (*n* = 543 patients)[@bib0540] have shown that it reduces fasting blood glucose levels and improves blood lipid profiles. Its primary mechanisms of action may relate to enhancement of peripheral glucose uptake[@bib0545] and through insulinomimetic or secretagogue activity.[@bib0375], [@bib0550]

Finally, the genus *Taraxacum* (dandelion), found in the temperate zone of the northern hemisphere, has been shown to possess antidiabetic and pancreatic beta cell protective effects due to nontoxic bioactive components found in all parts of the plant (some with high concentration in the roots) that include chicoric acid, triterpenes/phytosterols (taraxasterol), chlorogenic acid and sesquiterpene lactones.[@bib0555], [@bib0560], [@bib0565], [@bib0570] Furthermore, these phytochemicals demonstrate lipid-lowering effects,[@bib0575], [@bib0580], [@bib0585], [@bib0590] as well as antioxidant, anticancer, and anti-inflammatory properties.[@bib0555], [@bib0595], [@bib0600], [@bib0605]

All herbal components used in SR2004 are classified as 'generally recognized as safe' (GRAS) by the US Food and Drug Administration. To test the possibility of a synergistic effect of combining plant extracts, based on the available knowledge of the predominant mechanisms of action of the components, a smaller initial unpublished pilot/safety study was conducted by the authors on 52 patients with T2DM. This compared the effect on HbA1c of *Morus alba* latex extract, to a mixture of *Urtica dioica* with *A. dracunculus* (leaf extracts), versus SR2004 in liquid form. There was a reduction in HbA1c at 12 weeks of 10.5%, 14%, and 28%, respectively with no significant side effects reported in all groups (data available on request).

The objectives of this study were, therefore, to evaluate the effect of SR2004 on HbA1c, fasting blood glucose levels, and the blood lipid profile in patients with T2DM.

The primary endpoints were HbA1c and fasting blood glucose after 12 weeks of study, with evaluation of the safety and tolerability profile.

The secondary endpoints were total cholesterol and triglyceride levels at 12 weeks.

2. Methods {#sec0010}
==========

2.1. Study design {#sec0015}
-----------------

This is a single center, unblinded, prospective interventional study conducted in Israel, with a minimum follow-up period of 12 weeks (ISRCTN12562776). Adult patients with T2DM were referred by local health insurance or hospital-based physicians, or self-referred. All patients were screened with regard to trial criteria at the first visit. If screening criteria were met, baseline tests were performed as per details in [Table 1](#tbl0005){ref-type="table"} at week −2 and week −1 and thereafter were assessed weekly to week 12 and then at week 24. Written informed consent was obtained from all patients. The trial protocol was approved by the Helsinki committee of Maccabi health services Israel (Reference number 20080395) and conducted as per Good Medical Practice guidelines. The patient characteristics are described in [Table 2](#tbl0010){ref-type="table"}.Table 1Parameters Checked at Baseline and During the Trial Follow-up PeriodTable 1Week no.−2−1012345678910111224Physical examination×××××Informed consent×Height/weight×××××Urinalysis××××Blood pressure, pulse×××××××General chemistry××××Lipids (total cholesterol, triglycerides)××××Complete blood count××××Hemoglobin A1c××××Fasting glucose××××××××××××××××Table 2Patient Characteristics and Medication Use at Trial EntryTable 2No. enrolled119No. completing 12 weeks follow up (Male/Female)103 (60/43)Median age years (range)57 (28--78)Mean weight kilograms (range)81 (49--135)Mean Body Mass Index (kg/m^2^)30.3Mean fasting glucose mg/dL (range)211 (107--513)Mean Hemoglobin A1c % (range)9 (6--17)Mean total cholesterol mg/dL (range)212 (100--706)Mean triglyceride mg/dL (range)266 (151--1520)Insulin use no. (% of total patients)13 (12.6%)Sulphonylurea use no. (% of total)19 (18.4%)Biguanide use no. (% of total)44(42.7%)Meglitinide uses no. (% of total)2 (1.94%)Combination oral hypoglycemic use no. (% of total)25 (24.3%)Antihypertensive medications % of total38%Anti-lipid medication (statins and fibrates) % of total45%[^1]

2.2. Inclusion criteria {#sec0020}
-----------------------

Inclusion criteria included a confirmed diagnosis of T2DM *and* any combination of oral hypoglycemics and/or insulin with a HbA1c 7.1--10% in the last 6 months, body mass index (BMI) \< 45 kg/m^2^, ability to provide written informed consent, and no participation in an investigational drug study (or use of herbal supplementation) within the prior 30 days. Women of childbearing age were required to have a negative pregnancy test and use contraception for the duration of the trial.

2.3. Exclusion criteria {#sec0025}
-----------------------

The exclusion criteria included Type 1 diabetes mellitus, treatment with the drugs acarbose or rosiglitazone for more than 2 weeks in the last six months, a concomitant condition such as malignancy, heart failure grade 2--4 (American Heart Association), liver dysfunction (alanine aminotransferase or aspartate aminotransferase more than 3 times upper limit of normal values) or renal failure (serum creatinine more than 1.3 times upper limit normal for women and 1.4 for men), and a history of severe psychiatric illness on medication.

Lipid-lowering medications such as Ezetimibe and Lomitapide were not used.

2.4. SR2004 herbal composition {#sec0030}
------------------------------

The composition includes leaves of *M. alba* L., the leaves of *U. dioica* L., the bark of *Cinnamomum* (all of Unicorn Natural Products, Telangana, India), leaves of *A. dracunculus* L. (Jiaherb Phytochem, Xi'an, China), and *Taraxacum officinale* L. root extract (Stryka Botanics, New Jersey, USA). All botanicals received certificates of authenticity and purity from suppliers. The processing and extraction technique is described in detail in the European patent EP2170360B1. In summary, the leaves and flowers were cleaned and processed fresh (i.e.: while retaining their original color, shape, and turgor) with a combination of cutting, pressing, and heat extraction with brewing to maximize the extraction of plant products, including leaf latex. After this, the liquid was rapidly cooled to 20--30 degrees Celsius and then filtered. The root and bark components were cleaned and then processed using heat extraction followed by cooling. The mixed solution comprised (by weight percent of the total solution weight) 50% *Morus*, 20% *Artemisia*, 10% *Urtica*, 10% *Cinnamomum*, and 10% *Taraxacum*. This produced a liquid formulation that was used in the initial 56 patients at a dose of 300 milliliters (mL) three times a day, 30 minutes before meals. Because of the feedback of trial participants on the bitterness of the solution, a dry powder compound in the form of a capsule containing 500 milligrams (mg) with 40% herbal extracts (with the same percentage composition by dry weight) and 60% inert calcium phosphate carrier was developed (Karmat Ltd, Ramot Menashe, Israel). The dose was 2 capsules three times a day, 30 minutes before meals taken with water.

High-performance anion-exchange chromatography with pulsed amperometric detection (HPAEC-PAD) was used to initially determine the concentration of DNJ -- a marker of *M. alba* -- in the liquid formulation (Bar Ilan University, Ramat Gan, Israel) Using HPAEC-PAD on a CarboPac MA1 column with sodium hydroxide gradient, a clear and measurable separation of the DNJ extract from the water content could be demonstrated. Thermal stability studies confirmed that DNJ was stable. This process was later used to determine the concentrations of the other constituent herbs in the solution. Using this method, the herbal concentrations of two 500 mg capsules were calculated equivalent to 300 mL solution.

2.5. Patient management and monitoring {#sec0035}
--------------------------------------

All patients continued their previously recommended diets, medical treatments, and exercise regimes. Alterations to the dose of hypoglycemic medications were made at the physician\'s discretion based on recorded glucose values. Where blood glucose control was achieved, a stepwise reduction in conventional hypoglycemic medications was initiated and closely monitored by the trial physician. Monitoring of patients during the trial period was performed according to the schedule in [Table 1](#tbl0005){ref-type="table"}. Where necessary, patients were also reviewed by their usual diabetes physician.

2.6. Sample size and statistical methods {#sec0040}
----------------------------------------

Using HbA1c at week 12 as the primary endpoint, with a reduction of 1.0% considered clinically relevant and a standard deviation of 1.2%, a required sample size of 90 was calculated.

Data analysis was conducted by the Statistical Laboratory, School of Mathematics, Tel-Aviv University.

The statistical paired sample *T*-test method was used to calculate the significance of changes in values from week 0 to week 12. If necessary, a nonparametric Wilcoxon Rank sum test was applied. Additionally, an analysis of covariance model was applied to the 12-week endpoint using the baseline value as a covariate. A *p*-value \< 0.05 was considered statistically significant.

3. Results {#sec0045}
==========

One hundred and nineteen patients were enrolled. One hundred and three patients (87%) completed at least 12 weeks of follow-up. Of the sixteen patients who did not complete the trial, twelve patients dropped out of the study for reasons that included poor adherence to the study protocol, inability to follow up, problems associated with the taste of the solution, difficulties in traveling with the solution, or serious intervening illness. Four patients (3%) did not complete the study due to flatulence or loose bowel movements. These sixteen patients were excluded from the final data analysis. [Fig. 1](#fig0005){ref-type="fig"} summarizes the recruitment and retention of the test.Fig. 1Flow diagram of trial recruitment and retention.

There were no significant baseline sex differences in blood levels of fasting glucose (*p* = 0.463), HbA1c (*p* = 0.696), triglycerides (*p* = 0.780), or total cholesterol (*p* = 0.140). No significant change in body weight was observed during the trial period.

3.1. Primary and secondary endpoints {#sec0050}
------------------------------------

The results are summarized in [Table 3](#tbl0015){ref-type="table"}. Nine patients (9%) had no changes in the primary endpoint values and three patients (3%) showed an increase.Table 3Primary and Secondary Endpoint ResultsTable 3EndpointBaseline mean (SD)Week 12 mean (SD)Percentage change*p*-valueHemoglobin A1c9.1% (1.9)7.1% (1.2)−22\<0.0001Fasting blood glucose211 mg/dL (65)133 mg/dL (38)−37\<0.0001Total cholesterol213 mg/dL (85)185 mg/dL (42)−13\<0.01Triglycerides266 mg/dL (244)160 mg/dL (81)−40\<0.0001

Improvements in biochemical parameters were typically observed from week three of the study and were maintained during supplementation with SR2004.

Of thirteen patients treated with insulin at the beginning of the study, five reduced their daily dose by an average of 30% and five other patients managed to control their disease with only oral hypoglycemic agents while taking SR2004. All of them subsequently demonstrated the deterioration of the biochemical parameters within four months after the interruption of the SR2004 supplementation and required an increase in the conventional hypoglycemic treatment.

There were no serious events reported. In 14 patients (14%) and abdominal pain in 2 patients (2%), minor symptoms of abdominal discomfort, flatulence, or increased bowel movements were reported.

3.2. Additional clinical observations {#sec0055}
-------------------------------------

Several cases demonstrated improvement of vascular phenomena such as impotence (five men resumed sexual activity; three had been using Sildenafil concurrently), renal impairment (*n* = 3; maintained during SR2004 treatment), and limb claudication (*n* = 2). Improvement in established retinopathic changes was also seen, including two patients who had prior photocoagulation but were found to have "normalized fundoscopic findings with no diabetic retinopathy" by an independent ophthalmologist who had been monitoring them with serial clinical assessments. Although early retinopathy can revert with normalization of blood glucose values, the reversal of established severe retinopathic changes (in this case with prior photocoagulation) has only been described in the context of intraocular antivascular endothelial growth factors (anti-VEGF) treatments such as bevacizumab and pegaptabnib[@bib0610] rather than systemically active agents. The retinopathic observations are summarized in [Fig. 2](#fig0010){ref-type="fig"}.Fig. 2Clinical observations of patients with retinopathy and clinically significant macula edema. Effect of SR2004 supplementation and withdrawal on retinal appearances in patients with retinopathy and clinically significant macula edema. Group 1 (prior photocoagulation therapy, *n* = 4) and Group 2 (no prior photocoagulation, *n* = 4).

4. Discussion {#sec0060}
=============

This study is the first to evaluate the effect of the herbal composition used in SR2004 on blood glucose and lipid profiles in human subjects with T2DM who take conventional diabetic drugs and lipid reducers. It shows statistically significant reductions in serum levels of HbA1c, fasting blood glucose, triglycerides and total cholesterol with a good safety and tolerability profile when combined with other medications in a "real world" clinical setting. The clinical effects were typically apparent after week 3 and were maintained with continuous treatment. The results were independent of weight changes or activity levels; in fact, there was no significant weight reduction in the group as a whole.

On the basis of previous animal, human and *in vitro* studies of the effects of the constituent compounds used in SR2004, it is probable that glucose homeostasis is influenced by effects in multiple anatomic and cellular locations. These include the inhibition of intestinal disaccharidase activity, lectin-mediated binding of intestinal carbohydrate residues, upregulation of gluconeogenesis, reduction of tissue insulin resistance and glycolysis, with additional effects on insulinomimetic activity or secretory activity of pancreatic beta cells.[@bib0375], [@bib0380], [@bib0385], [@bib0390], [@bib0395], [@bib0400], [@bib0405], [@bib0410], [@bib0415], [@bib0420], [@bib0425], [@bib0430], [@bib0435], [@bib0440], [@bib0445], [@bib0450], [@bib0455], [@bib0460], [@bib0465], [@bib0470], [@bib0475], [@bib0480], [@bib0485], [@bib0490], [@bib0500], [@bib0505], [@bib0510], [@bib0520], [@bib0525], [@bib0530], [@bib0535], [@bib0540], [@bib0545], [@bib0550], [@bib0555], [@bib0560], [@bib0565], [@bib0570] The resultant effects are a reduction in postprandial and basal glucose levels.

It is recognized that chronically high levels of glucose in T2DM (called glucose toxicity) *in itself* leads to a deterioration in insulin secretion and a possible defect in glycogen synthesis.[@bib0615] Garvey et al, in a study of insulin therapy in patients with T2DM, showed a partial reversal in the postbinding defect of peripheral insulin action, reversion to an almost normal basal hepatic glucose output and enhanced endogenous insulin secretion when glycemic control was improved.[@bib0620] In their study, the average daily insulin requirement decreased by approximately 23% after two weeks of therapy and stabilized thereafter. Similarly, in our cohort, 10 of 13 patients treated with insulin were able to suspend insulin or reduce their dose by one-third on average through improved blood sugar control.

Diabetic dyslipidemia is a common finding characterized by a lipoprotein pattern of a modest elevation in triglycerides, an increase in low density lipoprotein cholesterol (LDL-C) particles and reduced levels of high density lipoprotein cholesterol (HDL-C). The LDL-C, in particular, are highly atherogenic due to their greater susceptibility to oxidative modification with greater absorption by the arterial wall and promote the macrovascular problems found in T2DM. With triglyceride levels above 132 mg/dL, small LDL-C particles become common and are the most potent predictors of coronary artery disease. In its updated 2015 recommendations, despite moving away from treatment based primarily on LDL-C levels, the American Diabetes Association maintained a recommended LDL-C level of less than 100 mg/dL. With the exception of type 2 diabetics under 40 years of age without other cardiovascular risk factors, treatment with statins (moderate or high intensity) is currently recommended to achieve a reduction in LDL-C levels.[@bib0625] To date, no study has shown an incremental benefit in reducing cardiovascular risk with combination antilipid therapy, with the exception of a modest reduction in the risk of myocardial infarction in the IMPROVE-IT study comparing simvastatin and ezetimibe versus simvastatin alone (HR 0.936, 95% CI 0.89--0.99, *p* = 0.016).[@bib0630] In our cohort, the combination of SR2004 with therapy with statins or fibrates (liver PPARα activators) resulted in a significant reduction of total cholesterol and particularly triglycerides (mean reduction of 40%).

The reduction in LDL-C and triglycerides noted in this study can be explained, in part, by better glycemic control and a consequent reduction in lipolysis, but other mechanistic possibilities include a direct effect on lipid metabolism by activating PPARα/γ pathways. These ligand-activated transcription factors are found in a wide variety of body tissues and regulate the expression of several genes that play critical roles in the metabolism of lipids and lipoproteins. It has been shown that PPAR activation increases β-oxidation of fatty acids in the liver, which is associated with large reductions in serum lipids and adipose tissue mass and is considered an important part of lipid homeostasis.[@bib0440], [@bib0635], [@bib0640] Additional consequences of PPAR activation include transcriptional upregulation and release of adiponectin, an adipocyte protein hormone[@bib0645], [@bib0650] with systemic effects that include reduced hepatic gluconeogenesis, increased triglyceride clearance, and reduction in Tissue necrosis factor alpha (TNFα) and interleukin 6 (IL-6), both important proinflammatory cytokines increased in obesity that promote lipolysis and insulin resistance. Several studies both *in vitro* and *in vivo* have demonstrated PPAR receptor activation and increased production of adiponectin after treatment with *Artemisia, Morus* and *Urtica*,[@bib0375], [@bib0465], [@bib0480], [@bib0545], [@bib0560], [@bib0655], [@bib0430] which may be part of a mechanistic explanation of SR2004.

It was observed that some patients in this study had significant improvements in vascular ischemic phenomena associated with diabetes, including claudication of the limbs, impotence, renal dysfunction due to renovascular disease, and most interestingly, the reversion of proliferative retinopathy in two cases. The mechanism underlying these improvements is not elucidated and this study was not designed to investigate them further, but it raises some interesting possibilities which deserve discussion. In general, the macrovascular complications of diabetes are due to accelerated atherosclerosis due to the combined effects of elevated LDL-C levels, peripheral insulin resistance, and, commonly, hypertensive endothelial stress. As discussed, the activation of PPAR and increased adiponectin levels would be expected to have beneficial effects on atherosclerotic plaques and macrovascular disease. However, the pathological mechanisms underlying microvascular complications characterized by thickening of the basal membranes, loss of pericytes, neovascularization, and the formation of microaneurysms probably include different factors. Oxidative stress may play an important role in cellular injury in hyperglycemia with the formation of free radicals and reactive oxygen species toxic to endothelial cells.[@bib0660] Neovascularization depends on the presence of several angiogenic factors, including nitric oxide (NO), prostaglandin-E2 (PGE2), and cytokines, such as VEGF, interleukin-1β, interleukin 6 (IL-6), and TNFα. Systemic levels of VEGF are often increased in diabetic patients and high intraocular levels are typically observed in those with proliferative changes due to elevated levels of hypoxia-inducible factor (HIF), a transcription factor, which in turn stimulates the release of VEGF-A.[@bib0665] Once bound to VEGF receptors on endothelial cells, angiogenesis is promoted through a tyrosine kinase-mediated pathway. In humans, the only strategy currently demonstrated to induce regression of retinal neovascularization involves local (intraocular) blockade of this pathway.[@bib0610] Two out of four patients in this study with established chronic retinopathic changes and previous laser photocoagulation showed a complete reversal of the fundal findings during the 12 weeks of follow-up. Xhu et al evaluated *in vitro* the effect of sesquiterpene lactones, flavonoids and coumarins derived from *Artemisia annua* L. on NO production induced by lipopolysaccharides and a variety of angiogenic cytokines including VEGF, TNFα, and IL-6 in rat mesothelial and mononuclear cells from human peripheral blood.[@bib0670]Their findings indicated that several metabolites derived from *Artemisia* were antiangiogenic and that the flavonoids casticin and chrysosplenol D demonstrated potent dual-inhibition of NO and PGE. Whether these properties are beneficial *in vivo* has not been investigated in humans to our knowledge and would seem to be a suitable line of investigation.

This study has some limitations which include a potential referral bias, with either more motivated patients seeking out the trial, or those with the disease at the more severe end of the diabetic spectrum being referred. The effect of SR2004 in patients with well-controlled blood sugars, on conventional diabetic medications, is not determined. Furthermore, the study was unblinded as the initial formulation was a liquid with distinctive appearance and taste which required refrigeration. The subsequent successful development of flavorless capsules makes a blinded study feasible, along with the introduction of a control arm.

In conclusion, this study demonstrates the herbal composition SR2004 improved levels of HbA1c, blood glucose, and lipids, in a group of patients with T2DM, regardless of weight changes, activity levels or the use of conventional diabetic medications and lipid-reducing medications. Interesting vascular effects -- including reversal of chronic retinopathic changes in some patients -- were observed during the 12-week trial and returned during the 12-week observation period thereafter. Further research is required to determine the precise bioactive components in SR2004 and their mechanisms of action, as well as a double-blinded, crossover trial to corroborate the findings of this preliminary study.
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